I'll have more to say about $TMDX Q2 results after I meet with management next week in Boston. The short term will remain choppy around margins as they continue to invest in R&D, trials, logistics and international expansion. The long term story/thesis still looks very good assuming that CHOPS and OCS Kidney both unlock new TAM... OCS Heart 2.0 can accelerate growth... Europe begins to contribute... and margins bounce back. It's still early in August but we're now tracking at 33.6 flights per day, up +49% YoY. Last year July and August were the two worst months for flights. This year July and August are the two best months for flights. Q3 has always been a seasonally weak period for $TMDX. Last year, Q3 flights were down -14% from Q2. This year, Q3 flights are up +7% from Q2. Last
View on X ↗